- Details
- Arjun Gupta and Alicia Morgans join Charles Ryan to discuss the role of genetics and pain experience in cancer patients. The study aimed to determine whether the Carboxy-O-Methyltransferase (COMT) rs4680 SNP variant associated with higher cerebral dopamine levels and improved mood, is associated with quality of life (QOL) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) treate...
|
- Details
- Michael Morris joins Alicia Morgans to discuss a new initiative between the NCI and the FDA to accelerate drug approvals for cancer patients. There is a need for a more efficient, less burdensome, and faster drug development process for cancer patients. This new unit focuses on highly innovative, highly impactful trials in which one would have very focused endpoints to streamline drug testing and...
|
- Details
- Michiel Van der Heijden joins Alicia Morgans to discuss the NABUCCO trial, which investigated preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer. The study enrolled patients with Stage 3 disease, including both cisplatin-ineligible and cisplatin-refusing patients, with about 40% being node-positive. In cohort 1, high pathological complete response rates were observ...
|
- Details
- Matt Galsky joins Sam Chang in a conversation about the long-term results of CheckMate 274, a randomized phase III study that enrolled patients with muscle-invasive urothelial cancer at high risk for recurrence after radical surgery. Patients were randomized to receive adjuvant nivolumab or placebo, with adjuvant nivolumab given for up to a year. The study's co-primary endpoints were disease-free...
|
- Details
- Sam Chang and Karan Jatwani discuss a study looking at the impact of neoadjuvant or adjuvant chemotherapy for patients with invasive disease, T2 disease, and the role of nephroureterectomy and how these treatments may impact findings. The study analyzed the NCDB database from 2004 to 2018 and found that neoadjuvant chemotherapy use was associated with a significantly improved overall survival haza...
|
- Details
- Sam Chang and Karan Jatwani discuss the role of adjuvant chemotherapy, versus observation, in patients with upper urinary tracts with variant histology undergoing a radical nephroureterectomy. The study, which analyzed data from the National Cancer Database from 2004 to 2018, found no difference in overall survival between patients who received chemotherapy and those who did not. The study focused...
|
- Details
- In this conversation between Alicia Morgans and Professor Silke Gillessen, they discuss the advances and controversies in advanced prostate cancer. They talk about the changing landscape of treatment options, triplet therapy, and highlight several GU ASCO 2023 meeting presentations. This includes the overall survival data from the PROpel trial, which tested the combination of abiraterone and olapa...
|
- Details
- Srikala Sridhar joins Sam Chang in discussing long-term follow-up from the JAVELIN Bladder 100 trial of avelumab first-line maintenance for advanced urothelial carcinoma. The JAVELIN-100 study was conducted on patients with metastatic urothelial carcinoma who had received frontline platinum-based chemotherapy and achieved a disease response. These patients were then randomized to receive either av...
|
- Details
- Tanya Dorff and Alicia Morgans discuss testosterone suppression and recovery in prostate cancer patients. They review data presented by Dr. Nabid, an analysis looking at a large set of patients treated on two different clinical trials of radiation therapy plus different durations of androgen deprivation. With six months of androgen deprivation therapy (ADT), 75% of men recovered normal testosteron...
|
- Details
- Kosuke Tamekura joins Pedro Barata to discuss results from the International Metastatic Renal Cell Carcinoma (RCC) Database Consortium (IMDC) looking at outcomes of patients with brain metastases from renal cell carcinoma treated with first-line therapies. Data from over 40 institutions worldwide is being collected to assess patients' demographics and outcomes. Patients with brain metastases from...
|
